Related Experiment Video
Updated: Jun 27, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Inactivation by omeprazole of the carnitine transporter (OCTN2) reconstituted in liposomes
Lorena Pochini1, Mariafrancesca Scalise, Cesare Indiveri
1Department of Cell Biology, University of Calabria, Via P.Bucci 4c, 87036 Arcavacata di Rende, CS, Italy.
Abstract:
The effect of omeprazole on the carnitine (OCTN2) transporter reconstituted in liposomes has been studied. Omeprazole externally added to the proteoliposomes, inhibited the carnitine/carnitine antiport catalysed by the reconstituted transporter. The inhibition was partially reversed by DTE indicating that it was caused by the covalent reaction of omeprazole with Cys residue(s) of the transporter. Similar results were found with intact brush border vesicles. The residual inhibition of the transport in the presence of DTE, indicated the occurrence of an alternative inhibition mechanism of non-covalent nature. The IC(50) of the two inhibition modes derived from dose-response curves, were 5.7 microM and 20.4 microM, respectively. Kinetic studies of the inhibition showed that in the absence of DTE omeprazole behaved as non-competitive inhibitor. On the contrary, in the presence of DTE competitive inhibition was found. The K(i) of the transporter for the inhibitor was 5.2 microM or 14.6 microM in the absence or presence of DTE, i.e., under condition of covalent (non-competitive) or non-covalent (competitive) interaction of the inhibitor with the transporter. The presence of the substrate during the incubation of the omeprazole (in the absence of DTE) with the proteoliposomes facilitated the covalent reaction of the pharmacological compound with the transporter. Omeprazole did not inhibit when present in the internal proteoliposomal compartment, indicating that the inhibition was specifically due to interaction with external site(s) of the protein. The pharmacological compound was not transported by the reconstituted transporter. The possible in vivo implications of the interaction of omeprazole with the transporter are discussed.
Insights
Omeprazole inhibits the carnitine transporter OCTN2 through both covalent and non-covalent mechanisms. This interaction, primarily at the external site, affects carnitine transport, with implications for in vivo drug effects.
Area of Science:
- Pharmacology
- Biochemistry
- Membrane Transport
Background:
- The carnitine transporter OCTN2 plays a crucial role in carnitine uptake.
- Omeprazole is a widely used proton pump inhibitor with potential off-target effects.
Purpose of the Study:
- To investigate the interaction of omeprazole with the carnitine transporter OCTN2.
- To elucidate the mechanisms and kinetics of omeprazole-mediated inhibition of OCTN2.
Main Methods:
- Reconstitution of OCTN2 transporter in liposomes.
- Inhibition assays using proteoliposomes and brush border vesicles.
- Kinetic analysis and dose-response studies.
Main Results:
- Omeprazole inhibited OCTN2-mediated carnitine transport via both covalent and non-covalent mechanisms.
- Covalent inhibition involved reaction with cysteine residues and was partially reversible by DTE.
- Non-covalent inhibition was competitive, while covalent inhibition was non-competitive, with distinct IC50 and Ki values.
Conclusions:
- Omeprazole interacts with the external site of the OCTN2 transporter.
- The substrate facilitated the covalent interaction of omeprazole with OCTN2.
- The findings suggest potential in vivo implications for omeprazole's effect on carnitine homeostasis.
Related Concept Videos
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Drug Metabolism: Phase II Reactions
